Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers (scientific article)

CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer

Q36449203

Prediction of breast cancer risk based on profiling with common genetic variants

Q36583004

CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls

Q37048943

Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls

Q37307305

Breast Cancer Survival and Tumor Characteristics in Premenopausal Women Carrying theCHEK2*1100delCGermline Mutation

Q61970254

Empirical Bayes estimates of age-standardized relative risks for use in disease mapping

Q69417787

Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation

Q73966464

CHEK2-positive breast cancers in young Polish women

Q80128998

The regulation of CHK2 in human cancer

Q80551940

CHEK2*1100delC screening of Asian women with a family history of breast cancer is unwarranted

Q81244092

P433

issue

P407

language of work or name

English

Q1860

P304

page(s)

2750-2760

P577

publication date

2016-06-06

P1433

published in

Journal of Clinical Oncology

Q400292

P1476

title

Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers

P478

volume

Reverse relations

cites work (P2860)

Q56888162	A Clinical Decision Support Tool to Predict Cancer Risk for Commonly Tested Cancer-Related Germline Mutations
Q57111436	Association Between CHEK2*1100delC and Breast Cancer: A Systematic Review and Meta-Analysis
Q91045517	BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors
Q30238753	Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial.
Q91211233	Cancer genetics, precision prevention and a call to action
Q99243158	Comprehensive analysis and ACMG-based classification of CHEK2 variants in hereditary cancer patients
Q92524053	Computational analysis of high-risk SNPs in human CHK2 gene responsible for hereditary breast cancer: A functional and structural impact
Q92161965	Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons
Q92630618	Contralateral Prophylactic Mastectomy in Women with Unilateral Breast Cancer Who Are Genetic Carriers, Have a Strong Family History or Are just Young at Presentation
Q33712610	Current perspectives on CHEK2 mutations in breast cancer.
Q90292766	Editorial: Accomplishments, Collaborative Projects and Future Initiatives in Breast Cancer Genetic Predisposition
Q89253231	Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data
Q30234614	Endometrial cancer gene panels: clinical diagnostic vs research germline DNA testing
Q92480972	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes
Q64065191	Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years
Q38627916	Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication
Q64251583	Genetic Epidemiology of Breast Cancer in Latin America
Q37739048	Genetic modifiers of CHEK2*1100delC-associated breast cancer risk
Q91362827	Genetic predisposition to mosaic Y chromosome loss in blood
Q39370774	Germline Mutations in Triple-Negative Breast Cancer
Q91989205	Is prophylactic mastectomy justified in women without BRCA mutation?
Q39270600	Managing hereditary breast cancer risk in women with and without ovarian cancer
Q55603054	Nipple-sparing mastectomy in women at high risk of developing breast cancer.
Q99408631	Pathogenic Variants in CHEK2 Are Associated With an Adverse Prognosis in Symptomatic Early-Onset Breast Cancer
Q92804641	Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer
Q96577047	Personalized early detection and prevention of breast cancer: ENVISION consensus statement
Q88947898	Pervasive genetic testing
Q41011976	Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods
Q40094101	Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks
Q92710828	Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients
Q100402781	Statistical approaches for meta-analysis of genetic mutation prevalence
Q91178389	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer
Q92282131	The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers
Q52632715	Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention.
Q92036319	Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers

P356	DOI	10.1200/JCO.2016.66.5844
P932	PMC publication ID	5019754
P698	PubMed publication ID	27269948